Corporate Profile

Rigel currently has the following product candidates in development: fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP; a Phase 2 clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase 2 clinical trial for IgA nephropathy (IgAN). In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.

Recent News

More »
09/15/16Rigel Restructures to Focus on Fostamatinib Commercialization
Hires Eldon Mayer as first Chief Commercial Officer, Founder Donald Payan Retires SOUTH SAN FRANCISCO, Calif., Sept. 15, 2016 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced plans to build a commercial organization to support the potential launch of fostamatinib, its oral SYK inhibitor, for the treatment of chronic immune thrombocytopenia (ITP). The company recently reported that fostamatinib met the primary endpoint in the first of two identical Phase 3 studies in chro... 
Printer Friendly Version
08/30/16Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP
Conference call and webcast today at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 30, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, met the primary endpoint in the first of two double-blind studies in the FIT Phase 3 clinical program for the treatment of adult chronic/persistent immune thrombocytopenia (ITP).  The study (n=76) showed that 18% of patients receiving fostamatinib achi... 
Printer Friendly Version
08/29/16Rigel Announces Press Release and Conference Call Schedule on Tuesday, August 30, 2016
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) announced that the company will announce results of the first of two FIT Phase 3 studies of fostamatinib for patients with immune thrombocytopenia (ITP), at 7:00 a.m. Eastern Time (4:00 a.m. Pacific Time) on Tuesday, August 30, 2016.  The company will also host a conference call at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss the Phase 3 study results. Participants can access the... 
Printer Friendly Version

Upcoming Events

More »

There are currently no events scheduled.

Stock Quote

RIGL (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) - 0.13 (3.51%)
Data as of 09/29/16 4:00 p.m. ET   Refresh quote

Stock Chart

Stock chart for: RIGL.O.  Currently trading at $3.57 with a 52 week high of $4.06 and a 52 week low of $1.88.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources

E-mail Alerts

Sign up to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.